


Anteo Diagnostics Limited
(ASX:ADO)
Annual General Meeting 2016

Meeting Format

1. Chairman's Welcome
2. Formal Resolutions
3. Group CEO Report
4. Other Business
5. Meeting Close.



TEM image shows ~2 nm thick Mix&Go polymer films on 40 nm gold nanoparticles

Directors and Management in Attendance



Dr John Hurrell
Non-executive
Director



Dr Geoff Cumming
Non-executive
Director



Mr Rolf Sickman
Non-executive
Director



Mr Richard Martin
Non-executive
Director



Dr Jef Vangenechten
Group CEO



Mr Peter Harding-Smith
Group CFO & Company
Secretary



Ms Tamara Mills
COO – Australian
Operations

Formal Resolutions

Resolution	Description
1	Adoption of Directors' Remuneration Report
2	Re-election of Director (Mr Rolf Sickman)
3	Re-election of Director (Dr Geoff Cumming)
4	Re-election of Director (Mr Mark Bouris)
5	Re-election of Director (Dr John Hurrell)
6	Approval of 10% Placement Facility
7	Ratification of Share Issue

Resolution Proxy Count

Res	Description	For	Against	Open	Excluded	Abstain	Totals
1	Adoption of Directors' Remuneration Report	248,024,387	79,096,799	15,395,282	45,802,884	11,388,480	399,707,832
2	Re-election of Director (Mr Rolf Sickman)	344,465,570	31,824,002	13,447,837	4,664,800	5,305,623	399,707,832
3	Re-election of Director (Dr Geoff Cumming)	318,180,664	40,452,253	18,072,637	22,833,333	168,945	399,707,832
4	Re-election of Director (Mr Mark Bouris)	Resolution withdrawn					
5	Re-election of Director (Dr John Hurrell)	280,300,827	84,256,275	19,042,637	0	16,108,093	399,707,832
6	Approval of 10% Placement Facility	246,197,574	134,358,400	18,015,589	0	1,136,269	399,707,832
7	Ratification of Share Issue	229,898,551	79,543,898	18,735,262	68,015,482	3,514,639	399,707,832

Group CEO Update

1. New Executive team
2. Anteo: a true platform technology
3. Group vision
4. Diagnostics
5. Medical Devices
6. Energy
7. Conclusions

New Executive Team



Dr Jef Vangenechten
Group CEO

- Appointed June 2016
- Extensive business experience
- In-depth Diagnostic Industry knowledge
- Ph.D. Biology/Physiology



Ms Tamara Mills COO
Australian Operations

- Appointed August 2016
- Extensive commercialisation experience
- Medical Device Background



Mr Peter Harding-Smith
Group CFO Company
Secretary

- Appointed October 2016
- Chartered Accountant
- ASX and capital market experience

A True Platform Technology



Anteo Nano-chemistry technology has applications in a number of different industries

Current Focus

1. **Diagnostics and life sciences:** effectively binding antibodies, antigens and other biological proteins to surfaces and beads (particles)
2. **Medical Devices:** to bond the nylon surface of sheaths and the lubricious hydrophilic coating.
3. **Energy:** Si anodes in Li-ion **batteries:** to prevent Si anodes from disintegrate because of swelling and shrinking during load/unload cycles.

Group Vision

sales and operational cash flows

operational maturity

Assay Development

DIAsource Platform

ISO Manufacturing

Commercialisation & BD

Group Vision

Diagnostic markets:


- PoC Development
- Products

Anteo Technologies

Medical Devices


Energy

Group Vision




Diagnostics and Life sciences

- **Core strengths**
 - Applying our technology at the *smallest scale* possible
 - Point of Care space
- **Executing on multiple partnering opportunities:**
Commercial value beginning to follow through
 - pi Planet Innovation
 - ellume illuminating healthcare
 - atomo diagnostics
- **Anteo and DIAsource are working together within the PoC space**



TEM images of Quantum Dots (10 nm) bound to Mix&Go activated magnetic nanoparticles (200 nm)


Diagnostic Revenue Sources




Financial strength DIAsource

- From 2014 to 2016 the yearly revenue grew from 11.8m € to over 15m €
- EBITDA increased from 10% to approaching 20% of revenue

Sales by Quarter - Q1 2014 to Q3 2016




Business Organization DIAsource




Future Business Organization DIAsource

Synergy for commercialization and business development



Group Vision



Anteo — Medical Device

Our goal:

To collaborate with Medical Device partners to achieve better and safer outcomes for patients through innovative surface modification.




Multiple ongoing development collaborations with Cook Medical



Actively strengthening Anteo's IP position in the medical device space:


- Conductive fibres provisional filed October
- Core to applications within active implantable devices

Group Vision




Anteo Energy

- Anteo coating provides strong bonds between silicon and binder which enhances structural integrity.
 - Proof of principle data shows
 - Increased energy capacity
 - Increased battery life
- Simple drop-in technology to existing Li-ion battery manufacturing
- Key industry players showed, have indicated strong interest in our technology



Example of SEM images of electrodes after >500 deep charge/discharge cycles.



Anteo Energy

- Partner with expert Li-ion RnD partner to accelerate industry standard data package generation
- Intention of entering commercial development arrangements with one or more of the following organizations.



Panasonic

SAMSUNG

NEC



OSAKA Titanium technologies Co.,Ltd.

Conclusion

- Current capabilities:
 - Greater acceptance of Anteo's technology in the Diagnostic market
 - Increase financial strength with the acquisition of DIAsource
 - Deeper Commercial experience with the DIAsource and new Senior management team
- This will lead to:
 - Greater emphasis on commercialisation and underlying profitability
 - Increase focus on IP generation, combined with a solid IP strategy
 - Long term value creation
 - A shift from the exploring the technology to exploiting the technology

Thank you for your time, your interest
and your continued support

